“Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s282. doi:10.25251/skin.7.supp.282.